Cellectis, Harvard Bio deal

Cellectis granted Harvard Bioscience's Harvard Apparatus division exclusive, worldwide rights to manufacture and market its full line of electroporation-based instruments for research use only. Cellectis will receive a $1.3 million upfront payment and will retain some undisclosed annual licensing fees. The instruments include DermaVax, OncoVet, Hybrimune, Cyto-LVT-S and Cyto-LVT-P. ...